​

Genmab (GMAB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

GMAB Stock Forecast

Genmab (GMAB) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $38.50, with a high of $46.00 and a low of $31.00. This represents a 93.95% increase from the last price of $19.85.

$15 $22 $29 $36 $43 $50 High: $46 Avg: $38.5 Low: $31 Last Closed Price: $19.85

GMAB Stock Rating

Genmab stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (72.73%), 3 Hold (27.27%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 3 8 Strong Sell Sell Hold Buy Strong Buy

GMAB Forecast vs Benchmarks

TypeNameUpside
StockGenmab93.95%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts--6
Avg Price Target--$45.83
Last Closing Price$19.85$19.85$19.85
Upside/Downside--130.88%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25225--9
Dec, 24225--9
Nov, 24245--11
Oct, 24245--11
Sep, 24245--11
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 04, 2024Vikram PurohitMorgan Stanley$31.00$27.4113.10%56.17%
Aug 09, 2024Etzer DaroutBMO Capital$46.00$27.0769.93%131.74%
Jun 27, 2024Kaveri PohlmanBTIG$47.00$25.6783.09%136.78%
Jun 27, 2024Raghuram SelvarajuH.C. Wainwright$50.00$25.7194.48%151.89%
Jun 04, 2024Asthika GoonewardeneTruist Financial$53.00$28.8383.84%167.00%
Feb 23, 2024Etzer DaroutBMO Capital$48.00$29.1664.61%141.81%
Feb 06, 2023Leerink Partners$36.00$38.26-5.91%81.36%
Nov 28, 2022Matthew HarrisonMorgan Stanley$34.00$44.83-24.16%71.28%
May 02, 2022Cowen & Co.$38.00$34.918.85%91.44%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Oct 16, 2024H.C. WainwrightBuyBuyhold
Oct 11, 2024Cowen & Co.HoldHoldhold
Sep 20, 2024Johnson RiceBuyBuyhold
Sep 13, 2024H.C. WainwrightBuyBuyhold
Sep 09, 2024Morgan StanleyBuyBuyhold
Aug 20, 2024H.C. WainwrightBuyBuyhold
Aug 09, 2024Cowen & Co.HoldHoldhold
Aug 09, 2024BMO CapitalOutperformOutperformhold
Aug 01, 2024BTIGUnderperformUnderperformhold
Jul 19, 2024H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$0 $14 $28 $42 $56 $70 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.30$4.60$8.45$66.64-----
Avg Forecast$7.14$4.37$9.88$7.48$8.66$9.62$12.41$17.92$22.36
High Forecast$6.65$4.06$8.83$6.85$7.76$7.48$8.31$15.91$19.63
Low Forecast$7.53$4.60$10.45$8.36$9.91$14.02$14.13$20.13$23.89
Surprise %2.24%5.26%-14.47%790.91%-----

Revenue Forecast

$5B $13B $21B $29B $37B $45B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.11B$8.48B$14.60B$16.47B-----
Avg Forecast$9.75B$8.39B$14.05B$16.16B$21.64B$25.39B$29.23B$33.61B$39.61B
High Forecast$9.23B$7.94B$12.91B$15.89B$20.78B$24.04B$29.06B$33.41B$35.89B
Low Forecast$10.16B$8.74B$14.68B$16.44B$22.57B$26.31B$29.40B$33.81B$41.70B
Surprise %3.65%1.10%3.89%1.92%-----

Net Income Forecast

$0 $8B $16B $24B $32B $40B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.76B$2.96B$5.45B$4.35B-----
Avg Forecast$29.77B$15.19B$14.90B$4.35B$582.45M$708.62M$739.70M$1.19B$1.47B
High Forecast$23.81B$12.15B$11.92B$3.48B$511.65M$492.95M$547.90M$1.05B$1.29B
Low Forecast$35.72B$18.22B$17.88B$5.22B$653.26M$924.29M$931.50M$1.33B$1.57B
Surprise %-84.02%-80.53%-63.41%------

GMAB Forecast FAQ

Is Genmab stock a buy?

Genmab stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Genmab is a favorable investment for most analysts.

What is Genmab's price target?

Genmab's price target, set by 11 Wall Street analysts, averages $38.5 over the next 12 months. The price target range spans from $31 at the low end to $46 at the high end, suggesting a potential 93.95% change from the previous close price of $19.85.

How does Genmab stock forecast compare to the average forecast of its sector, industry, and investment themes?

Genmab stock forecast shows a 93.95% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Genmab over the past three months?

  • January 2025: 22.22% Strong Buy, 22.22% Buy, 55.56% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 22.22% Strong Buy, 22.22% Buy, 55.56% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 18.18% Strong Buy, 36.36% Buy, 45.45% Hold, 0% Sell, 0% Strong Sell.

What is Genmab’s EPS forecast?

Genmab's average annual EPS forecast for its fiscal year ending in December is 8.66 for 2024, a -87.00% decrease from the reported $66.64 in 2023. The prediction for 2025 is $9.62, $12.41 for 2026, $17.92 for 2027, and $22.36 for 2028.

What is Genmab’s revenue forecast?

Genmab's average annual revenue forecast for its fiscal year ending in December is $21.64B for 2024, a 31.37% increase from the reported $16.47B in 2023. The forecast for 2025 is $25.39B, $29.23B for 2026, $33.61B for 2027, and $39.61B for 2028.

What is Genmab’s net income forecast?

For its fiscal year ending in December, Genmab's average annual net income forecast is $582.45M for 2024, reflecting a -86.62% decrease from the reported $4.35B in 2023. The projection for 2025 is $708.62M, $739.7M for 2026, $1.19B for 2027, and $1.47B for 2028.